Previous Article | Next Article ![]()
Journal of Virology, April 2001, p. 3706-3718, Vol. 75, No. 8
Department of Microbiology and Immunology,
University of North Carolina at Chapel Hill, Chapel
Hill,1 and Bayer Corporation,
Clayton,2 North Carolina
Received 7 November 2000/Accepted 29 January 2001
Venezuelan equine encephalitis virus (VEE) is an important equine
and human pathogen of the Americas. In the adult mouse model, cDNA-derived, virulent V3000 inoculated subcutaneously (s.c.) causes
high-titer peripheral replication followed by neuroinvasion and lethal
encephalitis. A single change (G to A) at nucleotide 3 (nt 3) of the 5'
untranslated region (UTR) of the V3000 genome resulted in a virus
(V3043) that was avirulent in mice. The mechanism of attenuation by the
V3043 mutation was studied in vivo and in vitro. Kinetic studies of
virus spread in adult mice following s.c. inoculation showed that V3043
replication was reduced in peripheral organs compared to that of V3000,
titers in serum also were lower, and V3043 was cleared more rapidly
from the periphery than V3000. Because clearance of V3043 from serum
began 1 to 2 days prior to clearance of V3000, we examined the
involvement of alpha/beta interferon (IFN- Venezuelan equine encephalitis
virus (VEE) is a member of the Alphavirus genus in the
Togaviridae family. The genome of this enveloped virus is a
single-stranded, messenger-sense RNA molecule of approximately 11.5 kb
(24), capped at the 5' end and polyadenylated at the 3'
end. The genomic RNA encodes four nonstructural proteins (nsP1 through
-4) and three structural proteins (capsid and two envelope
glycoproteins, E1 and E2). The 5' untranslated region (UTR) in VEE is
45 nucleotides (nt) long, and although its sequence is not conserved
among alphaviruses, the sequence predicts a stem-loop structure that is
conserved across the Alphavirus genus (55). It
has been proposed that the complementary sequence at the 3' end of the
minus strand also folds into a conserved secondary structure that may
play a role as a promoter for the initiation of genome RNA synthesis
from the minus-strand template (10, 38, 55). The
nonstructural proteins are translated directly from the genomic RNA as
a polyprotein that is cleaved by a viral protease to produce the enzyme
complex necessary for RNA replication. Thus, the 5' UTR is likely
involved both in translation of genomic mRNA and in initiation of
plus-strand RNA synthesis through interactions with host and/or viral
proteins. The structural proteins are expressed from an abundant 26S
subgenomic mRNA as a polyprotein. The precursor is cleaved into the
capsid protein that assembles to form the T=4 nucleocapsid, as well as
into two transmembrane glycoproteins, E1 and E2, that are arranged
within the viral envelope in a T=4 icosahedral lattice (39,
50).
VEE is an arthropod-borne virus that has been associated with periodic
epidemics and equine epizootics in the Western Hemisphere since the
1920s. These epidemics are associated with high mortality (19 to 83%)
and severe morbidity in equines and with up to tens of thousands of
human cases, with a case mortality rate of around 1% (21, 46,
61). Recent studies indicate that epizootic viruses can evolve
from enzootic equine-avirulent strains that circulate continuously
among wild rodents and Culex melanoconio mosquitoes in
lowland tropical forests (43, 60). The mechanism of
emergence and the molecular determinants of natural equine virulence
have been examined recently but are not well understood (34,
42).
Experimental infection of the adult mouse with VEE closely parallels
the biphasic disease seen in horses (12). In the mouse, subcutaneous (s.c.) inoculation with VEE is followed by initial viral
replication in the draining lymph nodes (DLN), viral spread to all of
the major lymphoid organs, and a significant viremia. This peripheral
infection is cleared by 3 to 4 days postinfection (p.i.). In the second
phase, VEE invades the central nervous system first through the
olfactory and trigeminal nerves, replicating predominantly in neurons
and causing lethal encephalitis (6, 13).
Molecular determinants of VEE virulence in the mouse model have been
studied using cDNA clones of wild-type virulent VEE and tissue
culture-adapted, attenuated strains, including the investigational live-attenuated vaccine strain TC-83 (2, 9, 13, 23, 40,
51). TC-83 was derived by serial passage of the virulent epizootic VEE Trinidad donkey strain (VEE-TRD) in guinea pig heart cells (3). Comparison of the nucleotide sequences of TRD
and TC-83 revealed 12 nucleotide changes. Mouse virulence studies of
chimeric TRD-TC-83 viruses suggested that two changes were associated
with the attenuated phenotype, a G-to-A substitution at nt 3 in the 5'
UTR and an E2-120 Thr-to-Arg mutation (23). It was
suggested that the 5' UTR and the E2-120 mutations represent two
independent loci that act synergistically in the attenuation of TC-83.
The contributions of several individual mutations in E1 and E2
glycoproteins to VEE virulence in mice have been well characterized
(4, 9, 13). However, the role of the 5' UTR in the
attenuation of VEE has not been addressed separately.
The involvement of alpha/beta interferon (IFN- Viral double-stranded RNA (dsRNA) replication intermediates are major
inducers of the IFN- Noncoding regions of many viral genomes carry virulence determinants,
including picornaviruses, influenza virus, retroviruses, and other
alphaviruses (1, 10, 36, 41, 44). For the prototype
alphavirus, Sindbis virus, 5' UTR mutants typically show defects in RNA
accumulation and altered growth rates in cell culture
(37). A single nucleotide change in the 5' UTR of Sindbis virus confers neurovirulence in rats (26). However, the
pathogenic mechanism at the molecular level has not been elucidated for
these alphavirus noncoding viral determinants.
In this study, the mutation in the 5' UTR of the TC-83 genome was
evaluated as to its effect on mouse virulence. A single change (G to A)
in nt 3 of the 5' UTR of the virulent V3000 genome resulted in a virus,
V3043, that was avirulent in mice and had reduced growth in cell
culture. In delineating the mechanism of attenuation in vivo and in
vitro, two possibilities were considered: an intrinsic defect in viral
replication and an altered interaction with the innate immune response.
Full-length cDNA clones of the virulent parent (V3000) and single-site
mutant (V3043) genomes were used as genetically stable sources of
homogeneous virus for infections of mice with a targeted disruption of
the IFN- Viruses.
The construction of the full-length cDNA clone
pV3000, derived from the natural VEE isolate, TRD, has been described
previously (9). Nucleotide 3 of the 5' UTR was changed
from G to A by site-directed mutagenesis. The 500-bp
XbaI-RsrII fragment of pV3000 was replaced with
the mutant fragment to produce pV3043, and the sequence of the replaced
fragment was confirmed. To produce virus stocks, pV3000 and pV3043 were
transcribed in vitro and the infectious RNA was electroporated into
baby hamster kidney cells (BHK-21; ATCC CCL-10) as described
previously (8). Virus particles were harvested from the
supernatant at 24 h p.i. (hpi) when significant CPE was produced and
were clarified by centrifugation (10,000 × g, 30 min,
4°C) and stored as single-use aliquots at
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.8.3706-3718.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Role of Alpha/Beta Interferon in Venezuelan Equine
Encephalitis Virus Pathogenesis: Effect of an Attenuating Mutation in
the 5' Untranslated Region
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
) activity in VEE
pathogenesis. In IFN-
/
R
/
mice, the course of the
wild-type disease was extremely rapid, with all animals dying within
48 h (average survival time of 30 h compared to 7.7 days in
the wild-type mice). The mutant V3043 was as virulent as the wild type
(100% mortality, average survival time of 30 h). Virus titers in
serum, peripheral organs, and the brain were similar in V3000- and
V3043-infected IFN-
/
R
/
mice at all time points up
until the death of the animals. Consistent with the in vivo data, the
mutant virus exhibited reduced growth in vitro in several cell types
except in cells that lacked a functional IFN-
/
pathway. In cells
derived from IFN-
/
R
/
mice, the mutant virus
showed no growth disadvantage compared to the wild-type virus,
suggesting that IFN-
/
plays a major role in the attenuation of
V3043 compared to V3000. There were no differences in the induction of
IFN-
/
between V3000 and V3043, but the mutant virus was more
sensitive than V3000 to the antiviral actions of IFN-
/
in two
separate in vitro assays, suggesting that the increased sensitivity to
IFN-
/
plays a major role in the in vivo attenuation of V3043.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
/
) in the virulence
of VEE for hamsters and mice was first proposed more than 25 years ago,
when pairs of virulent and benign isolates were compared with respect
to their sensitivity to IFN-
/
in cultures of hamster cells or in
vivo in hamsters (20, 22). These early studies showed a
correlation between virulence and relative resistance to IFN-
/
.
More recently, the IFN-
/
sensitivity of TC-83 and 24 enzootic and
epizootic isolates of VEE were compared in a tissue culture cytopathic
effect (CPE) reduction assay (54). The IFN-
/
resistance or sensitivity phenotype correlated with the epizootic or
enzootic potential, respectively, supporting the idea that one of the
adaptations leading to the emergence of epizootic strains is the
evolution of resistance to IFN-
/
(54). The
IFN-
/
sensitivity or resistance phenotype of chimeric viruses
containing the 5' UTR and nonstructural genes from either enzootic
(sensitive) or epizootic (resistant) strains of VEE seems to segregate
with the 5' UTR and nonstructural genes of the parental strain, even though it does not segregate with genes conferring guinea pig virulence
(42).
and IFN-
genes and cofactors in the
activation of IFN-induced antiviral enzymes (49, 56, 62).
Since cis-acting sequences involved in the regulation of alphavirus RNA replication are in the 5' UTR (55), it is
possible that virulence determinants in the 5' UTR of the VEE genome
might act through either a direct effect on viral replication and yield and/or an indirect effect on early host responses, such as IFN-
/
.
/
receptor gene and infections of cells derived from
these mice (35). In the absence of a functional
IFN-
/
pathway, V3043 replicated like V3000 in vivo and in vitro.
Our results demonstrated that IFN-
/
plays a major role in the
pathogenesis of V3000 and in the attenuated phenotype of the 5' UTR
mutant V3043. One mechanism is an increased sensitivity of V3043 to the
antiviral actions of IFN-
/
.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
70°C. Virus titers were
determined by a standard plaque assay on BHK-21 cells. For some
experiments, virus stocks were concentrated by pelleting the clarified
virus preparations through 20% (wt/vol) sucrose in low-endotoxin
phosphate-buffered saline (PBS) at 71,934 × g for
5 h at 4°C.
Mouse studies.
Specific-pathogen-free female CD-1 mice were
obtained from Charles River Breeding laboratories (Raleigh, N.C.).
Breeding pairs of IFN-
/
R+/+ 129Sv/Ev and
IFN-
/
R
/
mice were kindly provided by Herbert
Virgin (Washington University, St. Louis, Mo.) and Barbara Sherry
(North Carolina State University, Raleigh, N.C.), respectively. Mice
were bred under specific-pathogen-free conditions in the Department of
Laboratory Animal Medicine breeding colony facilities at the University
of North Carolina, Chapel Hill.
/
R
/
mice, which were bred in the same building, were acclimatized for 2 to
5 days in the biosafety level 3 laboratory before experimental manipulation. Standard mouse chow and water were provided ad libitum. Mice were between 6 and 8 weeks old when inoculated with virus.
For the morbidity and mortality studies, mice (8 to 11 per experimental
group) were anesthetized in a Metofane-saturated chamber and inoculated
s.c. in the left rear footpad (LRFP) or intracranially (i.c.) with
103 PFU of virus diluted in endotoxin-free PBS containing
1% donor calf serum (DCS) in a 10-µl volume by using a 27-gauge
needle and a 100-µl Hamilton syringe. Mock-infected animals received diluent alone. All mice except for IFN-
/
R
/
mice
were observed and weighed every 24 h for 14 days.
IFN-
/
R
/
mice were observed every 12 h. The
clinical signs of disease included ruffled fur, paresis, ataxia, and/or
paralysis. Morbidity was defined as greater than 10% weight loss
and/or clinical signs for two or more consecutive days. To confirm a
productive infection in the surviving mice, they were challenged with
104 PFU of V3000 inoculated intraperitoneally in a 100-µl
volume and were scored for morbidity and mortality for 14 days. All
previously inoculated mice survived this lethal challenge without morbidity.
To determine in vivo virus growth kinetics, mice were inoculated s.c.
in the LRFP with 103 PFU of virus. At various times
postinoculation, three mice per experimental group were anesthetized
with Metofane, the thoracic cavity was opened, and blood was collected
by cardiac puncture. The serum, separated in microtainer tubes, was
aliquoted and stored at
70°C. Each mouse was then perfused with
PBS-1% DCS to minimize the presence of blood-associated virus in the
organs to be collected. DLN, spleen, thymus, and brain were collected,
and PBS-1% DCS supplemented with Ca+ and Mg+
was added to make 20% (brain) or 10% (other organs) (wt/vol) suspensions in Kontes microfuge tubes. Samples were homogenized (Kontes
pestles) after one freeze-thaw and clarified by centrifugation at
10,000 × g. Samples were stored at
70°C prior to
processing. Virus titers were determined by a standard BHK-21 plaque assay.
Cells and in vitro infections.
BHK-21 cells, murine L929
fibroblasts (ATCC CCL-1), and murine Swiss 3T3 fibroblasts (ATCC
CCL-92) were maintained in alpha-minimum essential media (Gibco)
supplemented with 10% DCS, 10% tryptose phosphate broth, 0.29 mg of
L-glutamine/ml, 100 U of penicillin/ml, and 0.05 mg of
streptomycin/ml (37°C, 5% CO2). Primary bone marrow macrophages (BMM
) from 129Sv/Ev and IFN-
/
R
/
mice were generated as previously described (17). Briefly, the bone marrow cells were collected by flushing the bone marrow cavity
of the femur and tibia bones of cervically dislocated mice with cold
growth media. The cells were pelleted by centrifugation (60 × g, 4°C, 8 min) and resuspended in low-endotoxin Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (Gibco), 2 mM L-glutamine, 100 U of penicillin/ml,
0.05 mg of streptomycin/ml, and 20% of L-cell-conditioned media. The cells were seeded onto low-adherent bacterial dishes and allowed to
differentiate for 7 to 10 days.
were removed from the
low-adhesion dishes by using enzyme-free cell dissociation buffer
(Sigma) and then were seeded into 24-well plates at a density of 5 × 105 cells/well. The BHK, L929, and 3T3 cells were seeded
into 60-mm-diameter dishes and incubated at 37°C with 5%
CO2. When the monolayers were 80 to 90% confluent, the
media were removed and the cells were infected at a multiplicity of
infection (MOI) of 5 to 12 PFU/cell. After 1 h of adsorption at
37°C, the monolayers were washed three times with PBS-1% DCS at
room temperature, and complete growth medium was added to each dish. At
different times p.i., 70- or 20-µl aliquots of media were collected
and an equal volume of fresh media was added to keep the volume
constant. Samples were frozen at
70°C until analysis by plaque assay.
IFN-
/
assay.
The levels of murine IFN-
/
present
in serum from infected mouse and in supernatants from infected cell
cultures were measured by a standard biological assay on L929 murine
fibroblasts as previously described (58). Briefly, L929
cultures in 96-well plates were treated with standard murine
IFN-
/
(Lee Biomolecular) (twofold dilutions ranging from 1,000 to
0.49 IU/ml) or twofold dilutions of the experimental samples,
previously acid treated and neutralized. After 24 h of IFN-
/
treatment, the cells were infected with 2 × 105 PFU
of encephalomyocarditis virus (EMCV)/well in a 50-µl volume and
incubated at 37°C for 24 h. The remaining cells were then stained with 1% crystal violet. The percent CPE in each well was scored by direct observation. The IFN-
/
titers (IU/ml) were calculated based on the standard curves generated with commercial IFN-
/
; the end-point titer was calculated from the dilution of
IFN-
/
required to protect 50% of the cell monolayer from EMCV-induced CPE.
IFN-
/
sensitivity assay.
The relative sensitivity of
V3000 and V3043 to murine IFN-
/
was measured in murine fibroblast
L929 cells and Swiss 3T3 cells in a cell viability assay. The cells
were maintained in alpha-minimum essential media as described above and
used within five passages post-thaw. Cells seeded in 96-well plates
were treated with twofold dilutions of standard murine IFN-
/
(Lee
Biomolecular) in triplicate in doses ranging from 505 to 0 IU/ml. After
24 h at 37°C, the cells were infected with 2 × 106 PFU of virus (V3000 or V3043)/well or virus diluent in
a volume of 50 µl in the presence of 20,000 IU of rabbit anti-murine
IFN-
/
antibodies/ml (55,000 NIH neutralizing units per ml) (Lee
Biomolecular) to minimize the effect of virus-induced IFN-
/
. At
72 hpi, cell viability was determined by colorimetric quantification
using the MTT assay (mitochondrial dehydrogenase substrate) (Sigma
M5655) as described previously (52). Internal controls on
each plate consisted of unprimed infected cells, IFN-
/
-primed
uninfected cells, and unprimed uninfected cells. The percentage of
viable cells in each well was calculated relative to that of the
uninfected controls. These values were used to calculate the percentage
of CPE [(1
fraction of viable cells) × 100].
RNA isolation and analysis by RPA.
L929 cells grown in
60-mm-diameter dishes were treated with 0, 21, or 500 IU of murine
IFN-
/
/ml for 24 h at 37°C. The media were removed and the
cells were infected for 1 h at 37°C with V3000 or V3043 at an
MOI of 4 PFU per cell. The inoculum was removed and replaced with
prewarmed media. At 4 hpi, cells were placed on ice and harvested for
total cytoplasmic RNA by using the Ultraspec II RNA isolation system
(Biotecx). The levels of viral RNA were detected by an RNase protection
assay (RPA) using the RPAII system (Ambion). A negative-sense
VEE-specific riboprobe for the detection of plus-strand genomic and
subgenomic VEE RNA was constructed by inserting the 375-bp
BsrGI-BsgI fragment (nt 1925 to nt 2290) of V3000
into the SmaI-HindIII-digested pGEM-3
plasmid. The pG3V VEE plus-sense specific probe was made by using the
resulting plasmids, which were linearized at the unique
BsrGI site. In vitro T7 polymerase transcription reaction
mixtures (Maxiscript; Ambion) containing [
-32P]UTP
generated a 586-nt radiolabeled probe that would produce 405- and
163-nt protected fragments corresponding to genomic and subgenomic RNA,
respectively. As an internal control for this assay, a pGEM-GAPDH
plasmid, kindly provided by Charles Rice (School of Medicine,
Washington University, St. Louis, Mo.), was used to generate a specific
probe for the detection of cellular control GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) mRNA. The undigested probe
was 130 bp and the protected fragment was 116 bp. Ten micrograms of
total RNA was hybridized overnight at 45°C in 30 µl of
hybridization buffer to a molar excess of each radiolabeled probe
(routinely 1 × 106 to 2 × 106 cpm).
Unhybridized RNA was digested with RNase T1/RNase A mix, and the remaining RNA was precipitated. The protected radiolabeled RNA
was analyzed in 6% acrylamide-8 M urea-Tris-borate-EDTA gels and
visualized with a phosphorimager.
| |
RESULTS |
|---|
|
|
|---|
A single change in the 5' UTR of the VEE genome attenuates the
virus in mice after s.c. and i.c inoculations.
To assess the
individual contribution of the 5' UTR nt3A mutation to the attenuation
of VEE, we introduced that single change into the virulent,
TRD-derived, full-length cDNA clone (pV3000) and completely sequenced
the mutagenized region to ensure that no additional changes had been
introduced. The virulence of the resulting clone-derived virus, V3043,
was determined by comparing the morbidity and mortality rates of V3000
and V3043 in adult 129Sv/Ev mice after s.c. and i.c. inoculation (Table
1). As has been shown previously for CD-1
mice (4, 13), V3000 at a dose of 103 PFU was
virulent in 129Sv/Ev mice (100% morbidity and 100% mortality) following s.c. or i.c. inoculation, with similar average survival times
(AST) to those in CD-1 mice. In contrast, no mortality was observed in
mice inoculated with V3043 by the s.c. route, nor did they show
clinical signs of disease. By the i.c. route, all the mice inoculated
with V3043 showed signs of disease (ruffled fur, paresis, and/or more
than 10% weight loss) but nevertheless survived the infection (100%
morbidity, 0% mortality). Similar morbidity and mortality scores were
obtained with outbred CD-1 mice inoculated s.c and i.c. with V3043
(data not shown). All the mice infected with V3043 were protected
against a lethal challenge with 104 PFU of V3000,
confirming that they had undergone a productive V3043 infection.
|
Replication and spread of V3043 mutant virus in the mouse.
To
determine the point at which the replication of V3043 was restricted in
the mouse, time course studies were performed and the kinetics of virus
replication in various tissues (DLN, spleen, serum, and brain) were
determined after inoculation with 103 PFU of either V3000
or V3043 in the LRFP (Fig. 1A to D). At
12 hpi, replication of both viruses in the DLN and spleen resulted in
similar titers. After 24 hpi, the titers of V3043 in the spleen and
serum started to decline. By 48 hpi, V3043 titers had dropped 2 to 2.5 logs from the peak titer, and by 72 hpi, V3043 was below the limit of
detection in the serum, while V3000 titers were still 3 to 4 orders of
magnitude higher. In the DLN, the drop in titer was slower than that in
the spleen and serum, and the difference in titers between V3000 and
V3043 was evident only by 96 hpi (data not shown). In the brains of
mice inoculated s.c., there were detectable levels of V3000, but not
V3043, at 24 hpi. The V3000 titers increased thereafter until death,
while the V3043 titers peaked at 48 hpi, with only one out of three
mice showing titers above the limit of detection. V3043 titers declined
to below the limit of detection by 96 hpi (data not shown). Therefore,
V3043 was able to replicate in the same tissues as V3000 and reached comparable titers early in the infection. However, V3043 titers were
lower at 48 hpi in spleen, serum, and brain. V3043 viremia was lower
and of shorter duration than that of V3000. Serum titers of both
viruses were above the threshold required for neuroinvasion in the
mouse (K. A. Bernard et al., personal communication). When V3043 was
injected directly into the brain, the kinetics of replication in brain
were similar to those of V3000 at early times p.i.; however, the mutant
virus was cleared from the brain while the wild-type virus continued to
replicate until the death of the animal (data not shown).
|
V3043 is as virulent as V3000 and grows to similar titers in
IFN-
/
R
/
mice.
The rapid, early clearance of
V3043 from spleen and serum suggested two possible mechanisms of nt3A
attenuation. The nt3A mutation may have a slightly reduced rate of
replication in one or more cell types that is detectable only after
amplification through several rounds of replication. Alternatively, the
mutation may affect the interaction of the virus with some aspect of
the host nonspecific innate immune response, such as induction of or
sensitivity to IFN-
/
. To distinguish between these two
possibilities, V3000 and V3043 infections were compared in
IFN-
/
R
/
mice (35), the congenic
background strain 129Sv/Ev, and cells derived from them. We
hypothesized that in the absence of a functional IFN-
/
pathway,
any effect of the nt3A mutation on the intrinsic growth of the virus
independent of the IFN-
/
response would be detected. The
virulence of V3000 and V3043 in the IFN-
/
R
/
mouse
was compared to that in the control mice after inoculating the animals
s.c. with 103 PFU of either virus (Fig.
2). V3000 infection of either the
IFN-
/
R
/
or normal 129Sv/Ev mouse resulted in
100% mortality, but the AST was significantly shorter in the
IFN-
/
R
/
mouse (30 h) than in the control 129Sv/Ev
mouse (7.7 days). The results indicate that V3000 replication in
control mice is significantly restricted by IFN-
/
but is not
sufficiently restricted to prevent the virus from causing a fatal
encephalitis, as reported earlier (15). In contrast to
results obtained with the 129Sv/Ev control mouse, in the
IFN-
/
R
/
mouse V3043 was as virulent as the
wild-type virus, causing 100% mortality with an AST similar to that of
V3000 (30 h). Even when mice were inoculated with lower doses
(102, 10, and 1 PFU), V3043-infected
IFN-
/
R
/
mice showed the same AST of
V3000-infected mice (30 h).
|
/
R
/
mouse, 6- to 8-week-old mice were
inoculated in the LRFP with 103 PFU of either virus. At
different times p.i., serum and selected organs were harvested in
triplicate as described for Fig. 1. The levels of virus in the DLN,
spleen, and serum of the IFN-
/
R
/
mice were
equivalent for both V3000 and V3043 and increased continuously with no
evidence of clearance until the death of the animal (Fig. 3). Under these conditions, V3043 did not
show a growth restriction in the organs tested, except for the brain at
27 hpi, in which the titers of V3043 were consistently lower than those
of V3000.
|
/
R
/
mouse (Fig. 3) with those in the 129Sv/Ev
mouse (Fig. 1). At 12 hpi, the titers of both viruses in the DLN of the
IFN-
/
R
/
mice were equivalent to those in the 129 Sv/Ev mice, suggesting that early replication in the DLN was not
significantly affected by either the nt3A mutation or the IFN-induced
antiviral state. However, in the next 24 h, IFN-
/
played a
crucial role and determined the kinetics of replication and spread for
both viruses and the outcome of the infection by V3043.
Growth of V3043 in cell culture is reduced in the presence,
but not in the absence, of a functional IFN-
/
pathway compared to
that of V3000.
To further examine the mechanism of attenuation of
this mutation, the in vitro growth phenotypes of V3000 and V3043 were
examined. Growth curves were performed in mouse fibroblast cell lines
L929 and Swiss 3T3, in the BHK-21 cell line, and in primary BMM
derived from 129Sv/Ev or IFN-
/
R
/
mice (Fig.
4). Triplicate monolayers of cells were
infected with either virus at an MOI of 5 to 12 PFU/cell (PFU
determined on BHK cells). At these MOIs, virtually 100% of the BHK,
L929, and 3T3 cells and IFN-
/
R
/
BMM
were
infected, as determined by infecting cells at equivalent MOIs with
replicon particles 5005-3000 (nt3G) or 5505-3000 (nt3A) and measuring
the percentage of cells expressing GFP. We consider these conditions
representative of single-step growth curves. At the same MOI, less than
3% of 129 BMM
expressed GFP, reflecting a reduced permissivity to
VEE replication, determined mainly by the status of the IFN-
/
system (see below). The specific infectivity (particle per PFU ratio)
of V3000 and V3043 in BHK-21 cells is equivalent (K. A. Bernard and R. E. Johnston, unpublished observation); therefore, infections at the
same MOI (BHK PFU/cell) can be compared. The relative infectivity of
both viruses in the other cell lines was similar when compared by
infecting the cells with GFP-expressing replicon particles derived from
the wild-type or the mutant sequence and measuring the percentage of
cells expressing GFP.
|
derived from 129Sv/Ev mice (Fig. 4A to D). Similar results were
seen in Neuro2A cells and primary mouse embryo fibroblasts from CD-1
mice (data not shown). Although the virus titers in the BMM
derived
from 129Sv/Ev were low, V3043 replication was even more restricted than
that of V3000 (Fig. 4D), as shown for the other more permissive cell lines.
These experiments were designed to infect all permissive cells at time
zero to limit the factors affecting the growth of V3043 to either an
intrinsic growth defect or an autocrine or endogenous IFN-
/
response. We hypothesized that in cells derived from
IFN-
/
R
/
mice, in which virus growth cannot be
affected by an autocrine or paracrine IFN-
/
response, an
attenuated growth phenotype would be the result of an intrinsic growth
defect. In BMM
cells derived from the IFN-
/
R
/
mice, both viruses grew to titers several orders of magnitude higher
than those in cells from normal controls. Interestingly, in contrast to
all other cell types, V3043 grew to titers similar to or even higher
than those of V3000 in BMM
from IFN-
/
R
/
mice,
suggesting that the nt3A mutation does not cause a major intrinsic
growth defect and that when the IFN-induced antiviral response was
functional, it was more efficient in controlling V3043 infection than
V3000 infection. The growth characteristics of V3000 and V3043 in the
BMM
from IFN-
/
R
/
mice were consistent with the
in vivo results presented in the previous section. These results
supported the hypothesis that IFN-
/
plays an important role in
the attenuated phenotype of V3043 and suggested that any
IFN-
/
-independent effect of nt3A mutation on virus growth would
play only a minor role.
Induction of IFN-
/
by V3000 and V3043 infections in cell
culture and in vivo.
To further dissect the role of IFN-
/
in
the attenuation of V3043, the nt3A mutation was examined for its effect
on the ability of VEE to induce IFN-
/
. The production of murine
IFN-
/
in vivo and in vitro was measured following infection with
V3000 and V3043. The amount of IFN-
/
present in the sera of CD-1
mice inoculated s.c. with 103 PFU of V3000 or V3043 was
proportional to the serum virus titers and followed similar kinetics.
Peak titers of IFN-
/
were observed 18 to 24 hpi in both V3000-
and V3043-infected mice, but higher titers were induced by the virulent
V3000 (up to 80,000 IU/ml) than by V3043 (up to 20,000 IU/ml) (data not
shown). Because serum IFN-
/
levels may reflect the levels of
virus replication and spread in the peripheral tissues, we compared the
wild-type and the mutant viruses in their ability to induce IFN-
/
after a single replication cycle. Wild-type R5005-3000 and mutant
R5505-3000 VRPs, which can only undergo one round of replication, were
used to infect 129Sv/Ev and IFN-
/
R
/
mice (Fig.
5A). Replicon particles contain a VEE
replicon genome containing the GFP gene instead of the structural
protein genes, with either nt3G (R5005) or nt3A (R5505). At 6 hpi, both
replicons induced detectable levels of serum IFN-
/
in both
strains of mice. No differences in induction were found between the
wild-type and mutant VRP infections, nor between the two strains of
mice at this time. At 12 hpi, the IFN-
/
levels in the serum of
IFN-
/
R
/
mice had dropped significantly compared
to the titers in the 129 Sv/Ev mice, but titers of the different VRPs
were similar within each mouse strain. At 24 hpi, the levels of
IFN-
/
in the serum had dropped in both mouse strains, being lower
for the IFN-
/
R
/
mice (at or below the lower limit
of detection of the assay) and again showing no differences between
them for the different VRPs. By 48 hpi, IFN-
/
could not be
detected in any sample (data not shown). Therefore, the IFN-
/
induction after a single round of replication in vivo was not different
in mice infected with the wild type compared to those infected with
nt3A mutant VRP. Interestingly, the kinetics of IFN-
/
induction
were different depending on whether or not the mice expressed the
receptor for IFN-
/
. The IFN-
/
induced early was not
dependent on the presence of the IFN-
/
receptor, while later, in
the absence of the IFN receptor, less IFN was induced.
|
/
induction in vitro, BMM
cells from
IFN-
/
R
/
mice were infected with either replicon
particle preparation at an MOI of 20. At 18 and 24 hpi, the titers of
IFN-
/
in the culture supernatants were determined by bioassay on
L929 cells (Fig. 5B). The IFN-
/
induced in the absence of the
IFN-
/
receptor and in further rounds of replication was
equivalent at 18 and 24 hpi in the culture supernatants whether cells
were infected with V5005-3000 or V5505-3000, confirming the in vivo results.
V3043 is more sensitive than V3000 to exogenous IFN-
/
in
infected cell cultures.
We next examined the effect of the nt3A
mutation on the sensitivity of the virus to the antiviral effect
induced by IFN-
/
. Two different assays were used to measure
IFN-
/
sensitivity. First, mouse fibroblast L929 or Swiss 3T3
cells that had been pretreated with increasing concentrations (0 to 506 IU/ml) of murine IFN-
/
for 24 h were infected with V3000 or
V3043 at an MOI of 10 to 20. The readout was virus-induced CPE at 72 hpi. To minimize the effect of the IFN-
/
produced by the infected cells on the readout of the assay, cells were infected in the presence
of 20,000 IU of anti-IFN-
/
antibodies/ml, since in their absence,
V3043 was not able to cause full CPE in the mock-IFN-treated controls.
The dose of anti-IFN-
/
antibodies was estimated based on the
maximum levels of IFN-
/
produced in such infected cultures (up to
10,000 IU/ml; data not shown). For both viruses, pretreatment with
IFN-
/
decreased the percentage of cells exhibiting CPE compared
to that of the untreated control, indicating that both were sensitive
to the antiviral effects of IFN-
/
(Fig.
6). The sensitivity curve of V3000 in
L929 cells was similar to that of the EMCV indicator virus used in this
assay (data not shown), with concentrations of 32 to 63 IU of IFN/ml
protecting 50% of the monolayer from virus-induced CPE. The
sensitivity curve of V3043 was shifted to the left, reflecting a
sensitivity to IFN-
/
that was 8- to 10-fold higher than that of
V3000 (Fig. 6A). IFN-
/
at 8 IU/ml was able to protect 50% of the
monolayer from V3043-induced CPE under infection conditions in which
both viruses were able to cause close to 100% CPE in the untreated
control. The increased sensitivity of V3043 to IFN-
/
was more
dramatic in Swiss 3T3 cells, in which 0.5 IU of IFN-
/
/ml
protected 50% in the V3043-infected culture, while more than 506 IU of
IFN-
/
/ml was required to protect 50% in the V3000-infected
culture (Fig. 6B).
|
/
was also shown by
analysis of viral RNA synthesis using an RPA. L929 cells were pretreated for 24 h with IFN-
/
at a high dose (500 IU/ml) or a low dose (21 IU/ml) or were mock treated with diluent. The cells were
then infected with V3000 or V3043 at an MOI of 4. At 4 hpi, total
cytoplasmic RNA was extracted for analysis of VEE genomic and
subgenomic RNA by RPA. The levels of genomic VEE RNA in the untreated
control cells were two- to threefold higher in the V3043-infected cells
than in the V3000-infected cells (Fig.
7). This result is consistent with the
one-step growth curves of the IFN-
/
R
/
cells and
with the hypothesis that the attenuation of V3043 is not the result of
a decreased ability of V3043 to replicate. When cells were pretreated
with 500 IU of murine IFN-
/
/ml, viral RNA was not detected in
either V3000- or V3043-infected cells, indicating that at high doses of
IFN-
/
, the replication of both viruses was suppressed, consistent
with the results in Fig. 6A. In contrast, when cells were treated with
21 IU of IFN-
/
/ml, the levels of V3043 RNA were reduced 78% in
comparison to those of the untreated control, while the levels of V3000
RNA were reduced by only 9%, even though the RNA levels in the
untreated control were higher for V3043. This result suggests that
relative to the wild type, the mutation at nt 3 in the V3043 5' UTR
mediates a higher level of RNA replication, higher intracellular dsRNA
levels, and greater sensitivity to IFN-
/
-induced antiviral
effector pathways and, consequently, attenuation in vivo.
|
| |
DISCUSSION |
|---|
|
|
|---|
The study of alphavirus virulence from a genetic perspective
has yielded a number of interesting observations, perhaps none more
interesting than the dramatic effects that a single nucleotide change
can have on the course of disease in an animal. This is illustrated by
the many examples of single-codon changes in alphavirus genomes, and
indeed alternative amino acid substitutions at a given codon, that
profoundly alter virulence and organ tropism (2, 4, 9, 13, 18,
25, 40, 51). The 5' UTR of the genome of alphaviruses, which has
been implicated in neurovirulence (10, 23, 26, 27, 33), is
a case in point. In mice, a single nucleotide change in the 5' UTR of
VEE or Sindbis virus acts synergistically with determinants in the E2
glycoprotein to cause attenuation (10, 23, 33). In this
study, we have examined the individual contribution of a single
nucleotide change in the VEE 5' UTR and have shown that it changes a
virus which invariably causes 100% mortality to one which causes no
deaths by either a peripheral or i.c. route of inoculation. In
dissecting the in vivo and in vitro growth properties of the mutant
virus, we have unveiled a major role for IFN-
/
in the attenuation
of this single mutant virus. Our study contributes not only to a better
understanding of alphavirus virulence but also of how the interplay
between the virus genetics and the innate immune response affects the
outcome of the infection.
Comparison of the pathogenesis of V3000 and V3043 revealed that the two viruses grew in the same tissues and replicated to similar titers through the first 12 hpi. After this time, however, a restriction in mutant replication was detected, peak titers in tissue and serum were reduced, clearance from the periphery was accelerated, and invasion of the central nervous system was delayed and less frequent. This profile suggested that the mutation in the 5' UTR did not necessarily impede growth at the single-cell level but more likely caused V3043 to be more susceptible to an early host response.
The relative roles of the innate response to alphavirus infection, such
as through the IFN-
/
system, and classical adaptive immune
responses have been examined (5, 5a, 15, 16, 25, 28, 30, 35, 48,
57). In genetically modified animals lacking elements of the
adaptive immune system, alphavirus infections appear less damaging than
those in their immunologically intact counterparts. However, the virus
typically is not cleared from the animal, which may ultimately die from
continued virus replication (5a, 11, 29, 30). In contrast,
defects in the IFN-
/
system render mice extremely susceptible to
lethal infection (15, 19, 35), even with alphaviruses that
do not cause any clinical illness at all in normal adult animals
(48). Clearly, the IFN-
/
system provides an earlier
and more protective benefit than adaptive immunity, the latter being
demonstrably harmful in some cases.
In the work presented here, a significantly shorter AST and a
10,000-fold increase in virus titers in the
IFN-
/
R
/
mice compared to those in normal mice
were evidence that IFN-
/
does significantly inhibit VEE
replication. These results were consistent with the mortality and AST
of V3000 in IFN-
/
R
/
mice compared to those in the
control mice reported by Grieder et al. (15). The
comparable virulence of V3043 and V3000 in the
IFN-
/
R
/
mice was consistent with the V3043 virus
being more susceptible than V3000 to the early host response. Any
mutation that reduces the replication competence of a virus could
render it more susceptible to an early immune response. However, we
predicted that an important growth defect would impair growth even in
the absence of a functional IFN response, as has been shown for the
Sindbis attenuating mutant TRSB-R114 (48). With the
exception of brain titers, this was not the case for V3043. V3043 brain
titers were consistently lower than V3000 titers at 24 hpi, suggesting
that tissue-specific differences in growth between V3000 and V3043 also
could contribute to the attenuated phenotype. Therefore, our in vivo
data do not completely rule out a minor effect of the nt3A mutation on
virus replication at the single-cell level, which could also indirectly
result in a virus more susceptible to an early host response. A closer
examination of the effect of nt3A on different steps in the replication
cycle of the virus in cells lacking a functional IFN-
/
pathway is necessary to better understand any IFN-independent effect. There may be
an altered interaction between the 5' UTR and specific cell factors
involved in translation or replication, higher endogenous levels of
antiviral enzymes in different tissues, or an undefined IFN-independent
mechanism in these tissues.
The attenuated phenotype of V3043 observed in vivo in the normal
mouse was mimicked in cultured mouse and hamster cell lines and
129Sv/Ev mouse primary cells, in which V3043 replicated more slowly and
to lower titers than V3000. The only cell culture in which V3043 did
not show reduced growth was in the BMM
from
IFN-
/
R
/
mice, consistent with the results from
the in vivo infections that suggested a significant role for
IFN-
/
in the reduced growth of V3043 in normal cells. We
predicted that in one-step growth curves produced in the absence of a
functional IFN-
/
system, any IFN-independent intrinsic growth
defect in V3043, such as reduced viral RNA or protein synthesis, would
be revealed. No growth reduction was observed; V3043 grew as well as,
or better than, V3000 in cells from the IFN-
/
R
/
mice, suggesting that the mutant virus did not have an intrinsic growth
restriction in these cells. Interestingly, the higher V3043 titers in
the absence of a functional IFN system support the hypothesis that nt3A
causes an early increase in genomic RNA replication (Fig. 7). This
could increase the induction or the activation of IFN-induced antiviral
proteins, which in the presence of a functional IFN-
/
response
could result in increased sensitivity to IFN-
/
but in its absence
could result in higher virus titers. The low permissivity of normal
BMM
for VEE replication could be the result of an autocrine or
paracrine IFN-
/
response mediated by IFN-
/
released by the
infected cells that would induce an antiviral state in the infected and
neighbor cells through the IFN-
/
receptor (48).
Alternatively, a priming effect mediated by high endogenous levels of
antiviral enzymes at the time of the infection could result in low permissivity.
Grieder and Nguyen (14) studied the growth kinetics of
V3000 in mouse primary peritoneal macrophages, either quiescent or activated with lipopolysaccharide or IFN-
prior to infection. Their
results showed peak titers of about 104 PFU/ml at 18 hpi
when infected at an MOI of 1. These titers are comparable to the ones
reported here for the BMM
, even though our experiments were
performed at higher MOIs (5 to 12) and used macrophages with a
different phenotype and stage of differentiation.
To explain the in vivo and in vitro phenotypic differences observed in
the presence and absence of a functional IFN pathway, we proposed two
hypotheses: (ii) V3043 could be inducing higher levels of IFN-
/
than V3000 and/or (ii) V3043 could be more sensitive to the antiviral
response induced by IFN-
/
.
To address IFN-
/
induction, we used identical virus
particles carrying either V3043 or V3000 replicon genomes so that
IFN-
/
induction could be measured without the confounding effects
of multiple rounds of viral replication and subsequent alterations in
the physiology of the host. We saw no differences in IFN-
/
induction between mutant and wild-type replicon particles in either normal or IFN-
/
R
/
mice. We would predict that
higher levels of RNA synthesis by V3043 would induce higher levels of
IFN-
/
, but our assays did not detect any difference. However, an
interesting observation was made while addressing this question.
Analysis of the kinetics of IFN-
/
induction after a single round
of replication showed a prompt and transient response. However, early
IFN-
/
levels (6 hpi) were not affected by the absence of the
IFN-
/
receptor, while the faster drop of IFN-
/
titers in
the sera of IFN-
/
R
/
mice compared to those of the
normal mice suggested that feedback signaling through the IFN-
/
receptor was required for the continued production of IFN-
/
at 12 and 24 hpi. Recent studies have shown that in the absence of Stat1,
only IFN-
4 is induced in response to Newcastle disease virus
infection, while the induction of other species of IFN-
require
signaling through the JAK-STAT pathway (involving new protein synthesis
of IFN itself and IRF7) (32). This observation could
explain our results of differential induction of IFN-
/
by both
V3000 and V3043 in the IFN-
/
R
/
mice compared to
induction in the normal mice.
When we compared the antiviral effects of murine IFN-
/
on V3000
and V3043 infections of murine fibroblasts, V3043 was 8- or >100-fold
more sensitive to IFN-
/
in L929 or Swiss 3T3 cells, respectively.
The mechanism of IFN-induced protection in the mouse fibroblasts
involves binding of IFN-
and IFN-
to the common receptor on the
cell surface, which triggers a cascade of events through the JAK-STAT
pathway. This results in the transcriptional induction of a large group
of IFN-stimulated genes, including RNA-dependent protein kinase, 2'-5'
oligoadenylate synthetase, RNase L, MX1, and adenosine deaminase. In
the infected cell, viral dsRNA replication intermediates bind to the
induced RNA-dependent protein kinase, 2'-5' oligoadenylate synthetase,
and/or adenosine deaminase as cofactors in the activation of these
activities (62). Future studies will address the mechanism
of increased sensitivity to IFN-
/
by determining what IFN
effector mechanisms are active in the inhibition of VEE and what the
relative sensitivity of the wild type and the nt3A mutant virus is to
those antiviral pathways.
Attenuation determinants affecting sensitivity to IFN have been described for other viral systems. IFN-sensitive mutants of mengovirus (53) as well as a mutant of Sindbis virus resistant to mycophenolic acid and ribavirin with increased sensitivity to chicken IFN (47) have been described. However, the genetic loci in the virus responsible for the IFN-sensitive phenotype have not been defined, and the mechanisms that mediate their increased sensitivity to IFN are poorly understood.
Our results are consistent with previous reports showing an
increased sensitivity to IFN-
/
of VEE strain TC-83 and
horse-avirulent enzootic strains compared to those of their virulent
counterparts (42, 54). These studies with chimeric viruses
showed that IFN-
/
sensitivity segregates with the 5' UTR and
nonstructural genes (42). Our studies go further and
associate the IFN-
/
sensitivity phenotype with a single locus in
the 5' UTR.
Alphaviruses are transmitted between vertebrate hosts by mosquito
vectors which acquire the virus by taking a blood meal from an infected
animal at a time of peak viremia (21). To insure a
sufficiently high titer of virus for mosquito transmission, one would
anticipate a selective pressure in favor of high-level virus
replication and RNA synthesis. Decreased RNA synthesis would lead to a
reduced viremia and concomitantly reduced fitness in nature. On the
other hand, high levels of dsRNA could lead to increased induction of
IFN-
/
as well as increased synthesis and/or activation of
IFN-
/
-related antiviral effector mechanisms. Therefore, increased
levels of RNA synthesis could also lead to the same negative fitness
result by evoking elements of the IFN-
/
system. In terms of
pathogenesis, either an increase or decrease in RNA synthesis would
predict decreased virulence. In the case of V3043, early RNA synthesis
is increased, the sensitivity of this virus to IFN-
/
is increased
by 8- to >100-fold, replication in the animal is decreased, and the
virus is avirulent.
Our working hypothesis to link the single nucleotide change at nt
3 of the 5' UTR to the loss of virulence in mice is as follows. Although computer-generated RNA secondary structures only imperfectly predict authentic interactions, the Zucker programs do suggest that nt
3 is involved in a stable stem structure (59). Secondary structures of the 5' UTR have been predicted for other alphaviruses (10, 38, 55). The change from G to A in V3043 is predicted to weaken this structure, which may create a more accessible 5' terminus. This altered structure could affect RNA synthesis directly, as the 3' end of the negative-strand complement serves as the promoter
for the synthesis of progeny positive-strand genomes. Alternatively,
the 5' and 3' ends of the genome may interact during RNA synthesis so
that alterations in the genomic 5' UTR could affect positive- and/or
negative-strand synthesis. Finally, release of the extreme 5' end of
the genome from the stem could increase translation initiation for the
nonstructural protein open reading frame, leading to increased levels
of viral replicase components and hence increased RNA synthesis.
(Preliminary evidence suggests that translation of nonstructural
proteins is elevated in rabbit reticulocyte lysates primed with V3043
RNA and that higher levels of nonstructural proteins are synthesized in
infected cells in culture.) We would predict that the increased
IFN-
/
sensitivity of V3043 is a result of higher levels of RNA
synthesis, leading to increased direct induction of IFN-
/
-related
antiviral effectors, increased activation of such effectors, or both.
Alternatively, increased IFN-
/
sensitivity could result from
slower viral inhibition of host protein synthesis, allowing continued
production of key antiviral activities in infected cells. This
hypothesis is consistent with (i) the highly virulent infection of
V3043 in IFN-
/
R
/
mice, (ii) the absence of a
growth differential between the wild type and V3043 in cells lacking a
functional IFN-
/
system, (iii) the lack of an early growth
inhibition of V3043, followed by decreased titers in organ and more
rapid clearance in normal animals, and (iv) reduced virulence.
While a number of individual elements of the hypothesis remain to be addressed, our characterization of this single nucleotide change in the 5' UTR presents the opportunity to pursue a more comprehensive examination of the dynamic interaction of virus and host at the earliest times in the disease process.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grant NS26681 from the NIH.
We thank Kristen Bernard, Mark Heise, Brett Lidbury, William Klimstra, and Kate Ryman for critical reading of the manuscript. We thank Barbara Sherry and the entire Johnston laboratory for stimulating discussions. We also thank Cherice Conner, Michael Hawley, Jacque Bailey, and Dwayne Muhammad for excellent technical assistance with cell cultures.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: 836 Mary Ellen Jones Bldg., CB 7290, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7290. Phone: (919) 966-4026. Fax: (919) 843-6924. E-mail: ljwhite{at}med.unc.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Almond, J. W. 1987. The attenuation of poliovirus neurovirulence. Annu. Rev. Microbiol. 41:153-180[CrossRef][Medline]. |
| 2. | Aronson, J. F., F. B. Grieder, N. L. Davis, P. C. Charles, T. A. Knott, K. W. Brown, and R. E. Johnston. 2000. A single-site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus. Virology 270:111-113[CrossRef][Medline]. |
| 3. | Berge, T. O., I. S. Banks, and W. D. Tigertt. 1961. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells. Am. J. Hyg. 73:209-218. |
| 4. | Bernard, K. A., W. B. Klimstra, and R. E. Johnston. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity and rapid clearance from blood of mice. Virology 276:93-103[CrossRef][Medline]. |
| 5. |
Byrnes, A. P.,
J. E. Durbin, and D. E. Griffin.
2000.
Control of Sindbis virus infection by antibody in interferon-deficient mice.
J. Virol.
74:3905-3908 |
| 5a. | Charles, P. C., J. Trgovcich, N. L. Davis, and R. L. Johnston. Immunopathology and immune modulation of Venezuelan equine encephalitis virus-induced disease in the mouse. Virology, in press. |
| 6. | Charles, P. C., E. Walters, F. Margolis, and R. E. Johnston. 1995. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 208:662-671[CrossRef][Medline]. |
| 7. | Cormack, B. P., R. H. Valdivia, and S. Falkow. 1996. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173:33-38[CrossRef][Medline]. |
| 8. | Davis, N. L., K. W. Brown, and R. E. Johnston. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787[Abstract]. |
| 9. | Davis, N. L., N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. Smith, and R. E. Johnston. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 183:20-31[CrossRef][Medline]. |
| 10. | Dubuisson, J., S. Lustig, N. Ruggli, Y. Akov, and C. M. Rice. 1997. Genetic determinants of Sindbis virus neuroinvasiveness. J. Virol. 71:2636-2646[Abstract]. |
| 11. | Fazakerley, J. K., A. Khalili-Shirazi, and H. E. Webb. 1988. Semliki Forest virus (A7[74]) infection of adult mice induces an immune-mediated demyelinating encephalomyelitis. Ann. N. Y. Acad. Sci. 540:672-673. |
| 12. | Gleiser, C. A., W. S. Gochenour, Jr., T. O. Berge, and W. D. Tigertt. 1961. The comparative pathology of experimental Venezuelan equine encephalomyelitis virus infection in different animal hosts. J. Infect. Dis. 110:80-97. |
| 13. | Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206:994-1006[CrossRef][Medline]. |
| 14. | Grieder, F. B., and H. T. Nguyen. 1996. Virulent and attenuated mutant Venezuelan equine encephalitis virus show marked differences in replication in infection in murine macrophages. Microb. Pathog. 21:85-95[CrossRef][Medline]. |
| 15. | Grieder, F. B., and S. N. Vogel. 1999. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology 257:106-118[CrossRef][Medline]. |
| 16. | Griffin, D., L. Levine, W. Tyor, S. Ubol, and P. Despres. 1997. The role of antibody in recovery from alphavirus encephalitis. Immunol. Rev. 159:155-161[CrossRef][Medline]. |
| 17. |
Heise, M. T.,
M. Connick, and H. W. Virgin.
1998.
Murine cytomegalovirus inhibits interferon gamma-induced antigen presentation to CD4 T cells by macrophages via regulation of expression of major histocompatibility complex class II-associated genes.
J. Exp. Med.
187:1037-1046 |
| 18. |
Heise, M. T.,
D. A. Simpson, and R. E. Johnston.
2000.
A single amino acid change in nsP1 attenuates neurovirulence of the Sindbis-group alphavirus, S.A.AR86.
J. Virol.
74:4207-4213 |
| 19. |
Hwang, S. Y.,
P. J. Hertzog,
K. A. Holland,
S. H. Sumarsono,
M. J. Tymms,
J. A. Hamilton,
G. Whitty,
I. Bertoncello, and I. Kola.
1995.
A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses.
Proc. Natl. Acad. Sci. USA
92:11284-11288 |
| 20. | Jahrling, P. B., E. Navarro, and W. F. Scherer. 1976. Interferon induction and sensitivity as correlates to virulence of Venezuelan encephalitis viruses for hamsters. Arch. Virol. 51:23-35[CrossRef][Medline]. |
| 21. | Johnston, R. E., and C. J. Peters. 1996. Alphaviruses, p. 843-898. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa. |
| 22. |
Jordan, G. W.
1973.
Interferon sensitivity of Venezuelan equine encephalomyelitis virus.
Infect. Immun.
7:911-917 |
| 23. |
Kinney, R. M.,
G. J. Chang,
K. R. Tsuchiya,
J. M. Sneider,
J. T. Roehrig,
T. M. Woodward, and D. W. Trent.
1993.
Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein.
J. Virol.
67:1269-1277 |
| 24. | Kinney, R. M., B. J. Johnson, J. B. Welch, K. R. Tsuchiya, and D. W. Trent. 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. Virology 170:19-30[CrossRef][Medline]. |
| 25. |
Klimstra, W. B.,
K. D. Ryman,
K. B. Nguyen,
C. A. Biron, and R. E. Johnston.
1999.
Infection of neonatal mice with Sindbis virus results in a systemic inflammatory response syndrome.
J. Virol.
73:10387-10398 |
| 26. |
Kobiler, D.,
C. M. Rice,
C. Brodie,
A. Shahar,
J. Dubuisson,
M. Halevy, and S. Lustig.
1999.
A single nucleotide change in the 5' noncoding region of Sindbis virus confers neurovirulence in rats.
J. Virol.
73:10440-10446 |
| 27. |
Kuhn, R. J.,
D. E. Griffin,
H. Zhang,
H. G. Niesters, and J. H. Strauss.
1992.
Attenuation of Sindbis virus neurovirulence by using defined mutations in nontranslated regions of the genome RNA.
J. Virol.
66:7121-7127 |
| 28. |
LeBlanc, P. A.,
W. F. Scherer, and D. H. Sussdorf.
1978.
Infections of congenitally athymic (nude) and normal mice with avirulent and virulent strains of Venezuelan encephalitis virus.
Infect. Immun.
21:779-785 |
| 29. |
Levine, B., and D. E. Griffin.
1993.
Molecular analysis of neurovirulent strains of Sindbis virus that evolve during persistent infection of scid mice.
J. Virol.
67:6872-6875 |
| 30. |
Levine, B.,
J. M. Hardwick,
B. D. Trapp,
T. O. Crawford,
R. C. Bollinger, and D. E. Griffin.
1991.
Antibody-mediated clearance of alphavirus infection from neurons.
Science
254:856-860 |
| 31. |
MacDonald, G. H., and R. E. Johnston.
2000.
Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.
J. Virol.
74:914-922 |
| 32. | Marie, I., J. E. Durbin, and D. E. Levy. 1998. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660-6669[CrossRef][Medline]. |
| 33. | McKnight, K. L., D. A. Simpson, S.-C. Lin, T. A. Knott, J. M. Polo, D. F. Pence, D. B. Johannsen, H. W. Heidner, N. L. Davis, and R. E. Johnston. 1996. Deduced consensus sequence of Sindbis virus strain AR339: mutations contained in laboratory strains which affect cell culture and in vivo phenotypes. J. Virol. 70:1981-1989[Abstract]. |
| 34. | Meissner, J. D., C. Y. Huang, M. Pfeffer, and R. M. Kinney. 1999. Sequencing of prototype viruses in the Venezuelan equine encephalitis antigenic complex. Virus Res. 64:43-59[CrossRef][Medline]. |
| 35. |
Muller, U.,
U. Steinhoff,
L. F. Reis,
S. Hemmi,
J. Pavlovic,
R. M. Zinkernagel, and M. Aguet.
1994.
Functional role of type I and type II interferons in antiviral defense.
Science
264:1918-1921 |
| 36. |
Muster, T.,
E. K. Subbarao,
M. Enami,
B. R. Murphy, and P. Palese.
1991.
An influenza virus containing influenza B virus 5'- and 3'-noncoding regions on the neuraminidase gene is attenuated in mice.
Proc. Natl. Acad. Sci. USA
88:5177-5181 |
| 37. |
Niesters, H. G., and J. H. Strauss.
1990.
Defined mutations in the 5' nontranslated sequence of Sindbis virus RNA.
J. Virol.
64:4162-4168 |
| 38. | Ou, J.-H., E. G. Strauss, and J. H. Strauss. 1983. The 5'-terminal sequences of the genomic of RNAs of several alphaviruses. J. Mol. Biol. 168:1-15[CrossRef][Medline]. |
| 39. |
Paredes, A. M.,
D. T. Brown,
R. Rothnagel,
W. Chiu,
R. J. Schoepp,
R. E. Johnston, and B. V. Prasad.
1993.
Three-dimensional structure of a membrane-containing virus.
Proc. Natl. Acad. Sci. USA
90:9095-9099 |
| 40. |
Polo, J. M., and R. E. Johnston.
1991.
Mutational analysis of a virulence locus in the E2 glycoprotein gene of Sindbis virus.
J. Virol.
65:6358-6361 |
| 41. |
Portis, J. L.,
S. Perryman, and F. J. McAtee.
1991.
The R-U5-5' leader sequence of neurovirulent wild mouse retrovirus contains an element controlling the incubation period of neurodegenerative disease.
J. Virol.
65:1877-1883 |
| 42. |
Powers, A. M.,
A. C. Brault,
R. M. Kinney, and S. C. Weaver.
2000.
The use of chimeric Venezuelan equine encephalitis viruses as an approach for the molecular identification of natural virulence determinants.
J. Virol.
74:4258-4263 |
| 43. | Powers, A. M., M. S. Oberste, A. C. Brault, R. Rico-Hesse, S. M. Schmura, J. F. Smith, W. Kang, W. P. Sweeney, and S. C. Weaver. 1997. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J. Virol. 71:6697-6705[Abstract]. |
| 44. |
Pritchard, A. E.,
M. A. Calenoff,
S. Simpson,
K. Jensen, and H. L. Lipton.
1992.
A single base deletion in the 5' noncoding region of Theiler's virus attenuates neurovirulence.
J. Virol.
66:1951-1958 |
| 45. | Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401[CrossRef][Medline]. |
| 46. |
Rico-Hesse, R.,
S. C. Weaver,
J. de Siger,
G. Medina, and R. A. Salas.
1995.
Emergence of a new epidemic/epizootic Venezuelan equine encephalitis virus in South America.
Proc. Natl. Acad. Sci. USA
92:5278-5281 |
| 47. | Rosenblum, C. I., and V. Stollar. 1999. SVMPA, a mutant of sindbis virus resistant to mycophenolic acid and ribavirin, shows an increased sensitivity to chick interferon. Virology 259:228-233[CrossRef][Medline]. |
| 48. |
Ryman, K.,
W. B. Klimstra,
K. B. Nguyen,
C. A. Biron, and R. E. Johnston.
2000.
Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism.
J. Virol.
74:3366-3378 |
| 49. | Samuel, C. E. 1991. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11[CrossRef][Medline]. |
| 50. | Schlesinger, S., and M. J. Schlesinger. 1996. Togaviridae: the viruses and their replication, p. 825-841. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lipincott-Raven, Philadelphia, Pa. |
| 51. |
Schoepp, R. J., and R. E. Johnston.
1993.
Sindbis virus pathogenesis: phenotypic reversion of an attenuated strain to virulence by second-site intragenic suppressor mutations.
J. Gen. Virol.
74:1691-1695 |
| 52. |
Sherry, B.,
J. Torres, and M. A. Blum.
1998.
Reovirus induction of and sensitivity to beta interferon in cardiac myocyte cultures correlate with induction of myocarditis and are determined by viral core proteins.
J. Virol.
72:1314-1323 |
| 53. | Simon, E. H., S. Kung, T. T. Koh, and P. Brandman. 1976. Interferon-sensitive mutants of mengovirus. I. Isolation and biological characterization. Virology 69:727-736[CrossRef][Medline]. |
| 54. |
Spotts, D. R.,
R. M. Reich,
M. A. Kalkhan,
R. M. Kinney, and J. T. Roehrig.
1998.
Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5' noncoding region and glycoproteins.
J. Virol.
72:10286-10291 |
| 55. |
Strauss, J. H., and E. G. Strauss.
1994.
The alphaviruses: gene expression, replication, and evolution.
Microbiol. Rev.
58:491-562 |
| 56. | Tiwari, R. K., J. Kusari, and G. C. Sen. 1987. Functional equivalents of interferon-mediated signals needed for induction of an mRNA can be generated by double-stranded RNA and growth factors. EMBO J. 6:3373-3378[Medline]. |
| 57. | Trgovcich, J., J. F. Aronson, J. C. Eldridge, and R. E. Johnston. 1999. TNF-alpha, interferon and stress response induction as a function of age-related susceptibility to fatal Sindbis virus infection of mice. Virology 263:339-348[CrossRef][Medline]. |
| 58. | Trgovcich, J., J. F. Aronson, and R. E. Johnston. 1996. Fatal Sindbis virus infection of neonatal mice in the absence of encephalitis. Virology 224:73-83[CrossRef][Medline]. |
| 59. |
Walter, A. E.,
D. H. Turner,
J. Kim,
M. H. Lyttle,
P. Muller,
D. H. Mathews, and M. Zuker.
1994.
Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves predictions of RNA folding.
Proc. Natl. Acad. Sci. USA
91:9218-9222 |
| 60. |
Wang, E.,
R. Barrera,
J. Boshell,
C. Ferro,
J. E. Freier,
J. C. Navarro,
R. Salas,
C. Vasquez, and S. C. Weaver.
1999.
Genetic and phenotypic changes accompanying the emergence of epizootic subtype IC Venezuelan equine encephalitis viruses from an enzootic subtype ID progenitor.
J. Virol.
73:4266-4271 |
| 61. | Weaver, S. C., R. Salas, R. Rico-Hesse, G. V. Ludwig, M. S. Oberste, J. Boshell, and R. B. Tesh. 1996. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. Lancet 348:436-440[CrossRef][Medline]. |
| 62. | Welsh, R. M., and G. C. Sen. 1997. Nonspecific host responses to viral infections, p. 109-141. In N. Nathanson, R. Ahmed, F. Gonzalez-Scarano, D. E. Griffin, K. V. Holmes, F. A. Murphy, and H. L. Robinson (ed.), Viral pathogenesis. Lippincott-Raven, Philadelphia, Pa. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»